Two Sigma Advisers
SLNO

Two Sigma Advisers’s Soleno Therapeutics SLNO Stock Holding History

Two Sigma Advisers’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,467
Closed -$43K – 2713
2022
Q2 		$43K Sell
15,467
-960
-6% -$2.66K ﹤0.01% 2495
2022
Q1 		$55K Sell
16,427
-10,106
-38% -$52.3K ﹤0.01% 2581
2021
Q4 		$163K Sell
26,533
-23,067
-47% -$242K ﹤0.01% 2340
2021
Q3 		$688K Buy
49,600
+22,660
+84% +$316K ﹤0.01% 1788
2021
Q2 		$461K Sell
26,940
-2,373
-8% -$40.1K ﹤0.01% 1973
2021
Q1 		$554K Sell
29,313
-2,660
-8% -$85.7K ﹤0.01% 1973
2020
Q4 		$926K Sell
31,973
-14,720
-32% -$425K ﹤0.01% 1596
2020
Q3 		$1.76M Buy
46,693
+45,780
+5,014% +$1.34M 0.01% 1227
2020
Q2 		$30K Buy
+913
New +$39.6K ﹤0.01% 2446

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
CP
Clayton Partners Berkeley, California $152M AUM 42.38% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Advisers's SLNO Position: Q3 2022 in Review

Two Sigma Advisers sold out of Soleno Therapeutics (SLNO) in Q3 2022, closing a stake of 15,467 shares — an estimated $43K sold.

Two Sigma Advisers first reported a position in SLNO in Q2 2020 and held it in 9 quarters. The position peaked at $1.76M in Q3 2020. 22 funds tracked by Wall St. Rank hold SLNO as of Q3 2022.

  • Two Sigma Advisers reported no remaining Soleno Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 15,467 Soleno Therapeutics shares in Q3 2022, an estimated $43K.
  • Two Sigma Advisers first reported a position in Soleno Therapeutics in Q2 2020 and held it in 9 quarters.
  • Two Sigma Advisers's Soleno Therapeutics position peaked at $1.76M in Q3 2020.
  • 22 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2022.

Based on Two Sigma Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.